Robert Ainscow Sells 8,438 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 8,438 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $4.29, for a total value of $36,199.02. Following the completion of the transaction, the chief operating officer owned 2,248,441 shares in the company, valued at $9,645,811.89. The trade was a 0.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Robert Ainscow also recently made the following trade(s):

• On Wednesday, September 2nd, Robert Ainscow sold 25,000 shares of ASP Isotopes stock. The stock was sold at an average price of $3.90, for a total transaction of $97,500.00.

ASP Isotopes Trading Down 7.8%

Shares of ASP Isotopes stock opened at $3.31 on Friday. The company has a market capitalization of $507.46 million, a price-to-earnings ratio of -2.51 and a beta of 3.59. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76. ASP Isotopes Inc. has a 12-month low of $3.30 and a 12-month high of $14.49. The firm’s 50-day moving average price is $4.16 and its two-hundred day moving average price is $5.15.

ASP Isotopes (NASDAQ:ASPI) last issued its earnings results on Friday, August 14th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.11). ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%. The firm had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million.

Analyst Ratings Changes

ASPI has been the subject of several research analyst reports. Wall Street Zen upgraded shares of ASP Isotopes from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $13.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wyoming bought a new stake in shares of ASP Isotopes during the 1st quarter valued at approximately $29,000. Quantbot Technologies LP bought a new position in ASP Isotopes in the 3rd quarter valued at approximately $34,000. BNP Paribas Financial Markets boosted its position in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after buying an additional 2,548 shares in the last quarter. Stephens Inc. AR acquired a new stake in ASP Isotopes in the first quarter valued at approximately $44,000. Finally, Broadhurst Jeffrey B bought a new stake in shares of ASP Isotopes during the first quarter worth $44,000. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.